31
May

Eli Lilly wrestled its way into the spotlight at ASCO Saturday morning with evidence that its cancer drug ramucirumab delivers a marginal benefit for patients suffering from advanced non-small cell lung cancer. And analysts quickly heralded the data, saying it should help pave the way to quickly broaden the market for this drug.

…read more

Source: Lilly’s ramucirumab scores a marginal gain for lung cancer patients

    

0 No comments